

08.02.2023 – 13:26 Uhr

## Breakthrough - EUR 50 million investment for start-up BrainRepair UG / Pivotal trial on stem cell treatment for brain damage in newborns fully funded



Prof. Dr. med. Arne Jensen, MD  
Campus Clinic Gynecology  
Universitätsstr. 136  
44799 Bochum, Germany  
☎ +49 234 588 196-0  
✉ +49 234 588 196-19  
ame.jensen@brainrepair.eu

**MailOnline**  
By RACHEL REILLY  
PUBLISHED: 14:48 BST, 25 May 2013

### Boy, 2, is the first to have cerebral palsy 'successfully treated' using stem cells, taking him from a vegetative state to walking and talking



Doctors have successfully treated paediatric cerebral palsy with umbilical cord blood for the first time, on a patient known only L.S. They say the breakthrough dispels 'long-held doubts' surrounding the effectiveness of stem cell therapy

- The child was left in a vegetative state after going into cardiac arrest
- Doctors said his future was bleak and his chances of survival were minimal
- But German doctors performed stem-cell therapy using frozen blood from his umbilical cord stored at birth and now he can walk, talk and smile again
- Experts said the results dispel 'long-held doubts' about stem cell therapy

Doctors claim to have successfully treated a child suffering with cerebral palsy with stem cells for the first time.

Just weeks after being given an intravenous stem cell treatment from umbilical cord blood, the symptoms of a boy who had been left in a vegetative state after a heart attack improved considerably. Within months he could talk and move.

The German doctors who carried out the treatment say the results of the treatment dispel 'long-held doubts' surrounding the effectiveness of stem cell therapy.

Bochum, Germany (ots) -

Despite global economic and political crises, a London based group acquires 20% shares of BrainRepair UG, a spin-off of the Ruhr-University Bochum (RUB), Germany, that has developed a unique method based on own (autologous) cord blood stem cells to treat brain damage and cerebral palsy (CP) in newborns affecting 70,000 babies in the EU each year. BrainRepair UG has been granted the worldwide first 'Orphan Drug Designations' (ODD) by the European Commission / European Medicines Agency (EMA) and the Paediatric Investigation Plan (PIP) for the pivotal trial has been approved. The ODD guarantees market exclusivity in all EU member states for 12 years upon market authorisation. "We are particularly grateful to Olaf Bolwerk, Johan Nijboer, and Dr. Alexander van der Speld who masterminded the transaction to fund our way towards market authorisation", Prof. Dr. Arne Jensen stresses and continues, "All our personal, scientific, clinical, and philanthropic efforts serve the ultimate goal – to combat cerebral palsy, the most common disability in childhood – and stop CP in children!"

### About BrainRepair UG

BrainRepair UG is a clinical stage start-up developing cutting edge stem cell treatments based on human cord blood for a wide range of indications related to brain injury in children BrainRepair UG is the first Biotech company worldwide whose stem cell products have been awarded 'Orphan Medicinal Product Designations' for the treatment of brain injury in newborn infants (PVL, NE) by the European Commission / European Medicines Agency, EMA. BrainRepair's Headquarter is in Bochum, Germany. You may visit the website at <https://brainrepair.eu/> for more information.

### Links:

Jensen A. Cerebral palsy - brain repair with stem cells. J Perinat Med. 2022 Dec 12. doi: 10.1515/jpm-2022-0505. Epub ahead of print. PMID: 36503655.

<https://www.degruyter.com/document/doi/10.1515/jpm-2022-0505/html>

Jensen A. Autologous Cord Blood Therapy for Infantile Cerebral Palsy: From Bench to Bedside, *Obstet Gynecol Int* vol.2014,12p;

<https://www.hindawi.com/journals/ogi/2014/976321/>

Jensen A, Hamelmann E. First Autologous Cord Blood Therapy for Pediatric Ischemic Stroke and Cerebral Palsy Caused by Cephalic Molding during Birth: Individual Treatment with Mononuclear Cells", *Case Reports in Transplantation*, vol. 2016, Article ID 1717426, 9 pages, 2016.

<https://www.hindawi.com/journals/crit/2016/1717426/>

Jensen A, Neuhäuser G. Association of weight-length ratio at birth with psychomotor trajectories among preschool-aged children. *AJOG Glob Rep.* 2022 Oct 2;2(4):100115. doi: 10.1016/j.xagr.2022.100115. PMID: 36275404; PMCID: PMC9579794.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579794/>

Jensen A, Holmer B. "White Matter Damage in 4,725 Term-Born Infants Is Determined by Head Circumference at Birth: The Missing Link," *Obstetrics and Gynecology International*, vol. 2018, Article ID 2120835, 12 pages, 2018. [doi:10.1155/2018/2120835]

<https://www.hindawi.com/journals/ogi/2018/2120835/>

Contact:

BrainRepair UG (haftungsbeschränkt)  
Prof. Dr. med. Arne Jensen, MD, MBA  
Ruhr-University Bochum  
Campus Clinic Gynaecology  
Universitätsstr. 136  
44799 Bochum, Germany  
Tel.: +49 234 588 196-0  
Fax.: +49 234 588 196-19  
Email: arne.jensen@brainrepair.eu

## Medieninhalte



Figure: The first documented trial on transplantation of own (autologous) human cord blood stem cells after global brain damage caused by cardiac arrest (>25 mins) was performed as individual treatment of a boy 2.8 years of age on January 27, 2009 in Bochum, Germany. / More information via ots and [www.presseportal.de/en/nr/148654](http://www.presseportal.de/en/nr/148654) / The use of this image for editorial purposes is permitted and free of charge provided that all conditions of use are complied with. Publication must include image credits.

Original content of: BrainRepair UG, transmitted by news aktuell

Diese Meldung kann unter <https://www.presseportal.de/en/pm/148654/5436425> abgerufen werden.